Shire has agreed to sell its oncology business to Servier amidst takeover negotiations with Takeda Pharmaceutical. Shire’s oncology business consists of Onivyde® (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer and ex-US rights to Oncaspar® (pegaspargase) for the treatment of acute lymphoblastic leukaemia, which together generated sales of nearly US$262 M in 2017.